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This review  covers  recent  progress  on the  nature  of  the  mitochondrial  permeability  transition  pore  (PTP)
–  a  key effector  in  the mitochondrial  pathways  to cell  death  –  and  on  the  adaptive  responses  of  tumor
cells  that  desensitize  the  PTP  to Ca2+ and  reactive  oxygen  species  (ROS),  thereby  playing  an important
role  in  the  resistance  of  tumors  to cell  death.  The  discovery  that the  PTP  forms  from  dimers  of  F-ATP
synthase;  and  the  deﬁnition  of the  Ca2+- and  ROS-dependent  signaling  pathways  affecting  the  transitioneywords:
itochondria
ermeability transition
eactive oxygen species
-ATP synthase
of  the F-ATP  synthase  from  an  energy-conserving  to an  energy-dissipating  device  open  new  perspectives
for  therapeutic  intervention  in  cancer  cells.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).ancer
. Introduction
The deﬁnition of the permeability transition (PT) dates back
o almost 40 years ago, when Haworth and Hunter demonstrated
eversible opening of a channel in the inner mitochondrial mem-
rane that could be induced by Ca2+, phosphate, arsenate or oleic
cid, resulting in matrix swelling [1–4]. In the following years,
he permeability transition pore (PTP) was considered an in vitro
rtifact, and did not receive very much attention from the scien-
iﬁc community, with some notable exceptions (reviewed in [5]).
he interest on the PTP dramatically raised when it was discov-
red that it could be inhibited by a fungal peptide, cyclosporin A
CsA), following its interaction with a mitochondrial chaperone, the
eptidyl-prolyl cis-trans isomerase cyclophilin D (CyP-D; [6–11]).
n the same period, mitochondria took center stage in the pro-
ess of cell death, as it became clear that the effector phases of
ntrinsic apoptotic pathways were triggered by the release of apop-
ogenic proteins from mitochondria [12–17]. The PTP was  proposed
o act as an effector in the process of cell death [18]. Indeed, the
TP is a voltage and Ca2+-dependent, CsA-sensitive, high conduc-
ance channel, whose prolonged opening leads to a brisk increase in
∗ Corresponding authors at: Department of Biomedical Sciences, University of
adova, Via Ugo Bassi 58/B, I-35121 Padova, Italy. Tel.: +39 049 827 6365;
ax:  +39 049 827 6049.
E-mail addresses: rasola@bio.unipd.it (A. Rasola), bernardi@bio.unipd.it
P. Bernardi).
ttp://dx.doi.org/10.1016/j.ceca.2014.10.003
143-4160/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unthe permeability of the inner mitochondrial membrane to solutes
with molecular mass up to 1500 Da [19]. As a consequence, a bio-
energetic catastrophe occurs: equilibration of the proton gradient
causes mitochondrial depolarization, followed by respiratory inhi-
bition and generation of reactive oxygen species (ROS), massive
release of matrix Ca2+, swelling of mitochondria leading to breaches
in the outer mitochondrial membrane that induce the release of
intermembrane proteins. Thus, PTP opening prompts the demise
of the cell [20–23], and its (dys)regulation turned out to be a
crucial step in the pathogenesis of a variety of diverse diseases,
encompassing ischemia-reperfusion damage [20,24,25], lysosomal
storage diseases [26], liver damage [27,28], many acute and chronic
disorders of the central nervous system (reviewed in [29], colla-
gen VI myopathies [30] and cancer (reviewed in [31]). Therefore,
attempts to comprehend the molecular structure of the pore gained
momentum, but the protein composition of the PTP remained an
unsolved conundrum until very recently. This review covers recent
advances in the deﬁnition of the PTP structure, and its involvement
in the tumorigenic process.
2. Toward a deﬁnition of PTP structure
Electrophysiological experiments have shown a channel,
termed the “mitochondrial megachannel” (MMC)  in the inner
membrane endowed with high-conductance (≈1–1.3 nS) and all
the key regulatory features of the PTP: inhibition by CsA, ade-
nine nucleotides, Mg2+, acidic pH, and reducing agents; induction
by Ca2+ and voltage sensitivity [32–35]. Taken together, these
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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bservations leave little doubt that the MMC  is the PTP [36]. Dis-
ection of the protein composition of the PTP was  much more
omplex. At the turning of the century, a multimolecular PTP model
as proposed that included proteins of all mitochondrial compart-
ents, as it was postulated that these could aggregate at “contact
ites” between the outer and the inner membranes [37]. Follow-
ng this model, PTP components included CyP-D in the matrix,
he adenine nucleotide translocator (ANT) in the inner membrane
 the mitochondrial creatine kinase in the intermembrane space,
he porin/voltage-dependent anion channel (VDAC) in the outer
embrane, the isoform II of hexokinase (HK II) and the periph-
ral benzodiazepine receptor (PBR, now termed TSPO), together
ith Bcl-2 family proteins, externally associated on the mitochon-
rial surface. Despite its popularity, rigorous genetic analyses ruled
ut the possibility that any of these proteins could be part of
he core of the PTP ([38–40]; for detailed reviews on this topic,
ee [5,22]). However, the same genetic analyses demonstrate that
yP-D is a crucial regulator of the PTP. Indeed, ablation of CyP-D
enders the PTP insensitive to CsA and doubles the threshold Ca2+
oad required to open the PTP in the presence of phosphate anion
Pi) [41–44]. Notably, CyP-D can undergo several post-translation
odiﬁcations, including phosphorylation [45], acetylation [46],
nd nitrosylation [47,48]; CyP-D can also interact with a vari-
ty of proteins, such as Bcl-2 [49], the Ser/Thr kinase GSK-3 [45],
he chaperones Hsp90, TRAP1 [50] and Hsp60 [51], and the FOF1
TP synthase [52]. These dynamic changes of CyP-D affect the
TP, providing a remarkable level of ﬂexibility in its modes of
egulation.
An alternative model considered that the mitochondrial Pi car-
ier would form the PTP following its interaction with CyP-D and
NT [53]; however, this model still awaits genetic testing, while
esults obtained by patch-clamp analysis of the reconstituted Pi
arrier do not match with electrophysiological PTP features. It was
lso proposed that the PTP originates by clusters of misfolded pro-
eins [54], but this theory does not explain the strict PTP regulation
y pH, voltage and CsA (discussed in [5,22]).
Recently, our laboratory has proposed that the PTP is formed
y dimers of the FOF1 ATP synthase [55]. The mitochondrial ATP
ynthase is a large multiprotein complex composed by 15 sub-
nits, and it is formed by the catalytic, soluble F1 domain, which
rotrudes in the matrix, and by the inner membrane FO domain
hich allows the translocation of protons; the two domains are
onnected by a lateral and a central stalk [56]. The ATP syn-
hase is a rotary enzyme: in respiring mitochondria rotation of
he  subunit in the central stalk, caused by proton ﬂow across
he FO subunit induces conformational changes in the F1 subunit
hat elicit ATP synthesis, while the lateral stalk acts as a stator
57]. The functional unit of the enzyme is believed to be consti-
uted by ATP synthase dimers, which associate in long rows of
ligomers that shape cristae in the inner mitochondrial membrane
57–61].
CyP-D interacts with ATP synthase subunits b, d and OSCP,
hich are part of the lateral stalk of the enzyme; CyP-D interaction
equires Pi and partially inhibits ATP synthase activity, which can
e reverted by CsA, as it dissociates CyP-D form the enzyme [52].
yP-D shares the site of OSCP interaction with Bz-423, a compound
hat sensitizes the PTP to Ca2+, and we could demonstrate that this
ensitization is blocked at Pi concentrations that favor the interac-
ion between CyP-D and OSCP, which constitutes a ﬁrst functional
onnection between OSCP and the PTP [55]. More direct evidence
hat the PTP is constituted by ATP synthase, notably in its dimeric
orm, came from patch-clamp experiments performed on enzyme
imers puriﬁed by blue native gel electrophoresis. The measured
urrents closely matched the features of the MMC  channel, and
ere induced by Bz-423 in a Ca2+-sensitive way [55]. We pro-
osed that the PTP forms at the interface between two adjacent FOium 56 (2014) 437–445
subunits (Fig. 1), with OSCP acting as an inhibitor and CyP-D as an
inducer, which would lower Ca2+ concentration required to pro-
mote PTP opening after substituting Mg2+ binding to the enzyme
[5]. In accord with this model, our laboratory has recently demon-
strated that puriﬁed ATP synthase from yeast forms a channel with
properties similar to the mammalian PTP but of somewhat lower
conductance; and that ablation of e and g ATP synthase subunits,
which are required for dimer formation, leads to a marked resis-
tance to PTP opening [62].
It has been argued that detection of PTP opening in 0 cells
[63], which lack mitochondrial DNA and therefore ATP synthase
subunits a and A6L, speaks against involvement of dimers in pore
formation [64,65], but this is an erroneous conclusion based on a
misinterpretation of the literature. Wittig et al. [66] have shown
that dimers of ATP synthase do form in 0 cells, and have concluded
that “ATP synthase is almost fully assembled in spite of the absence
of subunits a and A6L”. Higher order ATP synthase structures are
less stable after digitonin treatment of 0 cells; yet, and although
their amount was  smaller, dimeric and even tetrameric forms of the
large assembly intermediate were preserved under the conditions
used for clear native electrophoresis, suggesting to the Authors that
the ATP synthase associated further into higher order structures in
the mitochondrial membrane [66].
Others have found that PTP induction by Ca2+ and oxidants is
related to the expression level of the c subunit of ATP synthase. The
c subunit forms a ring-shaped oligomer in the FO subunit that is
directly involved in proton ﬂux, and it was  shown that its transient
depletion by RNA interference prevents PTP opening, while its over-
expression strongly induces it [67]. This study does not bear on the
mechanism of PTP formation, however, because it did not inves-
tigate the consequences of knock-down of the c subunit on other
components of the ATP synthase.
Reconstitution of the puriﬁed c-subunit ring was reported to
form a voltage-sensitive channel leading to Ca2+-dependent mito-
chondrial depolarization and cell death, whereas both effects would
be inhibited in cells depleted of the c subunit [68]. It was suggested
that the PTP channel forms within the c ring after Ca2+-dependent
extrusion of F1, i.e.,  of the  subunits. We  note that displacement
of F1 requires quite drastic conditions, such as treatment with 2 M
urea [69]; yet the FOF1 complex can be easily reconstituted indi-
cating that the  subunits can reinsert into FO. Thus, it is hard to
see how Ca2+ could cause release of F1, and then create a channel
that cannot be closed by F1 [68].
Alavian et al. [68] have reported that the “FO channel” can
instead be blocked by the puriﬁed  subunit, and suggested that
this is the mechanism for pore closure in situ [68]. Structural stud-
ies have established that subunit  does not interact with the c ring,
however [57–61]; and a second, major problem with this proposal
is the source of matrix free  subunit, given the extreme resistance
of the F1 subcomplex to denaturation. It should be noted that chan-
nel openings were also observed with preparations of ATP synthase,
and that these could be inhibited by CsA after the addition of Ca2+
[68]. If the mechanism of pore opening is “expulsion” of F1 by Ca2+,
it is not easy to see how the current would be inhibited by CsA,
because the latter inhibits the PTP by removing CyP-D from F1, not
FO [52,55]. It should also be noted that earlier patch-clamp stud-
ies of highly puriﬁed c subunit yielded very different results, as
currents were activated by cGMP and inhibited rather than acti-
vated by Ca2+ [70–72]. It is legitimate to wonder whether in the
preparation of Alavian et al. other F-ATP synthase components were
present that could explain this major discrepancy.
Given that in our hands the PTP readily forms from gel-puriﬁed
ATP synthase dimers but not monomers, and that inactivation of
subunits e and g in yeast increases resistance of the PTP to Ca2+, we
still favor the idea that the pore forms at the interface between two
monomers in the dimeric enzyme [55,62].
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. PTP and tumors
Prolonged PTP opening constitutes the point of no return toward
he demise of the cell, irreversibly committing it either to apo-
tosis, provided that enough ATP is present to activate caspases,
r to necrosis, elicited by massive Ca2+ release in the cytosol and
y impairment of mitochondrial function. The capability to escape
ell death induction following exposure to stress conditions is
 mainstay of cell progression to malignancy [73,74], and most
hemotherapeutics are based on the possibility to selectively rein-
tate apoptotic programs in neoplastic cells. Therefore, a detailed
omprehension of PTP structure, and of its regulation in cancer con-
titute attractive approaches to develop anti-neoplastic strategies
imed at PTP induction.
.1. PTP and the redox equilibrium of cancer cells
Cancer cells exhibit changes in their redox status, with elevated
OS levels caused both by changes in their signaling pathways,
etabolic networks and mitochondrial function, and by exposure
o ﬂuctuating conditions of oxygen and nutrient supply in the sur-
ounding environment [75]. This increased level of ROS must be
ept under tight control by enhancing anti-oxidant defenses [76],
n order to avoid the detrimental effects of oxidants on a vari-
ty of cellular structures, which eventually lead to cell death [77].
his is particularly important in early tumorigenic phases, whereas
t later neoplastic stages high ROS levels could be tolerated, as
hey increase cell motility and invasiveness and promote geneticse dimers. Phosphorylation and acetylation of CyP-D favor its interaction with ATP
IMM,  inner mitochondrial membrane.
instability, thus contributing to increase malignancy of the grow-
ing neoplasm [78]. In these conditions, the eventual cellular fate
may  be the result of a delicate balance between ROS generation and
scavenging, and cancer cells are likely to be more vulnerable than
normal ones to further oxidative insults that outpace their anti-
oxidant defense mechanisms. Thus, agents that prompt oxidative
damage may  represent a strategy for selectively targeting cancer
cells, while sparing normal ones [79].
PTP induction is a key effector of death elicited by oxidative
stress [29]. Indeed, various pro-oxidant agents are able to induce
PTP opening. Oxidants increase intracellular Ca2+ release from the
endoplasmic reticulum and inhibit Ca2+ extrusion from the plasma
membrane [80], and mitochondrial Ca2+ enhances OXPHOS, and
therefore generation of ROS as by-products. Above a certain level,
mitochondrial Ca2+ or membrane hyperpolarization might also
produce ROS through inhibition of respiratory complexes and even-
tually by PTP induction, which completely stops electron ﬂow along
the respiratory chain and causes release of mitochondrial GSH
[81,82]. A transient PTP induction may  in turn induce short bursts
of ROS in the so-called ROS-induced ROS release (RIRR) [83,84].
Therefore, strategies to elicit PTP opening can be envisioned as
promising anti-neoplastic approaches, even if the possibility of
noxious side effects, e.g., on the nervous system or cardiac tissues,
must be carefully considered [85]. Conversely, CsA inhibition of
the PTP promotes skin cancer in transplant patients by allowing
keratinocyte survival under conditions of genotoxic stress, high-
lighting the key role of pore inhibition in tumor development
[86].
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Fig. 2. Mechanisms of PTP regulation in tumor cells. A variety of factors control tumor cell viability by modulating PTP opening, mainly by modulating ROS levels. A ROS surge
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Several molecules can induce ROS-dependent PTP opening
Fig. 2). Inhibition of a mitochondrial voltage-dependent K+ chan-
el, termed mtKV1.3, induces ROS production and a CsA-sensitive
itochondrial depolarization, indicating PTP opening. Inhibition
an be elicited by a speciﬁc residue on the pro-apoptotic protein
ax [87] or by the membrane-permeant, selective inhibitors Psora-
, PAP-1 and clofazimine, which induce death in several human
nd mouse cancer cell lines and in primary B-chronic lymphocytic
eukemia cells [88,89]; notably, intraperitoneal injection of clofaz-
mine reduced by 90% the size of a melanoma in an orthotopic
ouse model, without any side effect on healthy tissues [88]. Such
 selective effect of these drugs probably depends on their targeting
he altered redox equilibrium of neoplastic cells.
The uncoupling protein-2 (UCP-2) mediates proton leak across
he inner mitochondrial membrane [90]. UCP-2 overexpression
as reported in a number of tumor types [91], where it protects
rom oxidative stress, since a depolarizing proton leak is expected
o diminish superoxide production [92]. Moreover, a high level of
CP-2 inhibits apoptosis induced by chemotherapeutics [91] and
eads to development of tumors in vivo in an orthotopic model of
reast cancer [93]. It is reasonable to envision that UCP-2 might
hield tumor cells from ROS-induced PTP opening and death.
.2. Chemotherapeutics and the PTPA large number of compounds that induce the PTP, mainly
y inducing oxidative stress, are under scrutiny as potential
hemotherapeutics. Many of them, such as the plant-derived alka-
oid berberine [94], the plant hormone methyljasmonate [95], theects cells from noxious stimuli. PTP inducers are indicated in orange, PTP inhibitors
 c: cytochrome c; HK II: hexokinase II; IMM:  inner mitochondrial membrane; SB3:
monocyclic sesquiterpene alcohol -bisabolol [96], the naphtho-
quinone shikonin [97], the triterpenoid betulinic acid [98], the
constituent of turmeric powder curcumin [99], the polyphenolic
compounds resveratrol [100] and honokiol [101], and others, are
natural compounds that have been tested on tumor cell lines and
in vivo in preclinical animal models (for a complete review, see
[82,85]). Some of these molecules, including methyljasmonate,
resveratrol and curcumin are particularly promising and are cur-
rently undergoing clinical or pre-clinical trials [102].
Moreover, some widely used chemotherapeutics act at least in
part by inducing the PTP in a ROS-dependent way. Taxol (pacli-
taxel), whose main mechanism of action relies upon microtubule
stabilization, was shown to prompt ROS generation and PTP open-
ing both in puriﬁed liver mitochondria and in liver BRL-3A cells
[103]. In pancreatic cancer cells, cisplatin, whose mode of action
mainly depends on the formation of adducts with DNA that lead to
apoptosis [104], was  shown to trigger a CyP-D-dependent necrosis
[105], whereas hepatocellular carcinoma cells selected for cisplatin
resistance could undergo cell death after PTP induction [106]. These
data suggest that both paclitaxel and cisplatin have complex inter-
actions with the target cell, and PTP opening can contribute to their
anti-neoplastic effect. In the same line, we have recently found that
several chemotherapeutics, including cisplatin, doxorubicin and
the BH3 mimetic EM20–25 [107], induce a rapid rise of ROS lev-
els in hepatoma cells, leading to PTP opening and cell death [108].
Notably, overexpression of a serine protease inhibitor of the ser-
pin family, called SERPINB3 (SB3), installs an anti-oxidant defense
mechanism in these neoplastic cells: SB3 locates inside mitochon-
dria, mainly during oxidative stress, where it inhibits respiratory
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omplex I, thus blocking ROS generation following chemotherapeu-
ic treatment and protecting cells from PTP opening [108]. Indeed,
TP inhibition is an important adaptation that acts as a tumor-
romoting event in the model of hepatocarcinogenesis caused by
-acetylaminoﬂuorene in rats [109].
.3. GSK-3 and the PTP in cancer
The above data highlight the importance of PTP regulation in
umorigenesis, and indicate respiratory complexes as a primary
ource of ROS in neoplastic cells. A further connection among PTP
nduction, ROS generation and respiratory complexes came from
tudies on the serine/threonine kinase GSK-3. GSK-3 is a kinase cru-
ially involved in a variety of biological processes; it targets more
han 50 substrates, and it is placed at the crossroads of multiple
ransduction pathways, in multimeric complexes with scaffold pro-
eins, other kinases and substrates. Notably, GSK-3 is constitutively
ctive and exerts a tonic inhibitory effect on its targets, and can be
oth inhibited by phosphorylation on a Ser residue, or further acti-
ated by phosphorylation on a Tyr residue [110,111]. A fraction of
he enzyme, called mGSK-3, is located inside mitochondria [112],
here it down-modulates both the Krebs cycle [113] and oxida-
ive phosphorylation [114] and constitutes an integration point to
unnel a multiplicity of survival pathways to target(s) at or in close
roximity to the PTP [115,116].
A ﬁrst connection between respiration, GSK-3 and oxidative
tress in tumor cells came from the observation that activation
f the mitochondrial pool of GSK-3 enhances ROS production and
poptosis following treatment of human neuroblastoma cells with
omplex I inhibitors [114,117]. It was then demonstrated by us as
ell as others that in several tumor cell models mGSK-3 phospho-
ylates CyP-D, facilitating PTP opening [45,118]. CyP-D is a direct
arget of GSK-3, as a recombinant GSK-3 could phosphorylate CyP-D
n vitro; and the effect of GSK-3 on the PTP was increased after CyP-D
verexpression and absent in CyP-D knock-out cells [45]. Deregu-
ation of oncogenic signaling induced constitutive activation of the
inase ERK in a variety of tumor models [119]. We  observed that
 fraction of active ERK locates in mitochondria, where it inhibits
SK-3 by serine phosphorylation; this results in ablation of CyP-D
hosphorylation and in inhibition of PTP opening [45]. Therefore,
his mitochondrial kinase pathway contributes to the resilience to
ndergo death that characterizes neoplastic cells, and can be mod-
lated by drugs acting on any of its constituents. We  also found an
RK/GSK-3 dependent modulation of the PTP through CyP-D phos-
horylation in 0 cells [63]. These cells can be considered as an
xtreme case of the metabolic rearrangements that occur in tumor
ells, as they must completely rely on glycolysis for their metabolic
eeds. As already mentioned, despite the absence of subunits A6L
nd a of ATP synthase (which are encoded by mitochondrial DNA)
he PTP can be detected in 0 cells [63].
Recently we have demonstrated that the Gold(III)-
ithiocarbamato complex AUL12, gold-based chemotherapeutic
f new generation designed with the speciﬁc aim of improving
electivity, bioavailability, and efﬁcacy of platinum-based com-
ounds, diminishing their toxic side effects [120], elicits a rapid
urst of mitochondrial superoxide levels following inhibition
f the respiratory complex I [121]. ROS generated at complex I
nhance activation of GSK-3 by inducing its tyrosine phosphory-
ation. Active GSK-3 has a double effect of on PTP induction: the
itochondrial pool of the enzyme facilitates PTP opening through
hosphorylation of CyP-D, whereas the cytosolic pool interacts
ith Bax and prompts its mitochondrial translocation, where it
ontributes to PTP induction and tumor cell death [121]. Notably,
UL12 is much less toxic on non-transformed cells and it displays
ery low systemic toxicity after in vivo administration [122].ium 56 (2014) 437–445 441
In summary, several functional connections link in a complex
network respiration, oncogenic signaling cascades, mGSK3, ROS
levels and the PTP in tumor cells, making GSK-3 an appealing target
for drug discovery, even if the pleiotropy of its functions exposes
to the risk of undesired side effects.
3.4. Mitochondrial hexokinase II and the PTP
Hexokinase (HK) is the ﬁrst enzyme of glucose metabolism,
which converts glucose to glucose-6-phosphate. Four mammalian
hexokinase isoforms exist, and isoform II (HK II) is the one pre-
dominantly expressed in malignant cells. Several peculiar features
of HK II explain this switch: it harbors a very high afﬁnity for
glucose; it shows two  nearly identical protein domains that can
catalyze the phosphorylation of glucose, whereas in other hexoki-
nase isoforms one of these domains has lost its catalytic role; and,
together with HK I, it displays a N-terminal mitochondrial anchor-
ing domain, which allows HK II binding to the outer mitochondrial
membrane in order to maximally exploit mitochondrial ATP for glu-
cose phosphorylation [123]. All these elements make HK II a central
component of the metabolic rewiring of neoplastic cells toward an
efﬁcient glucose utilization, which has profound implications for
tumor progression. Indeed, many cancer types increase the use of
glucose, uncoupling it from oxygen availability (the Warburg effect;
[124–126]). This metabolic rearrangement favors neoplastic cell
expansion in the hypoxic conditions encountered in the core of the
tumor mass [127] and provides anti-oxidant defenses and anabolic
building blocks by inducing the pentose phosphate pathway [128].
Several lines of evidence functionally connect HK II to the PTP,
even if the different localization of these two  elements (external
mitochondrial surface vs. inner mitochondrial membrane) sug-
gests the importance of intermediate molecules whose nature is
currently unknown. Indeed, release of HK II from mitochondria
prompts apoptosis in hepatocellular carcinoma and glioma cells
[129,130]; and detachment of HK II from mitochondria by a selec-
tive peptide induces PTP opening and the subsequent apoptosis in
several tumor cell models [131].
HK II integrates a variety of signals that determine its asso-
ciation/dissociation with mitochondria, and therefore survival or
death, respectively, of tumor cells. Inactivation of cytosolic GSK-
3 through phosphorylation by the survival kinase Akt, whose
signaling is constitutively induced in most tumor types, favors
mitochondrial association of HK II, whereas GSK-3 activation elic-
its the release of HK II from the outer mitochondrial membrane,
increasing susceptibility to cell death [132,133]. Moreover, Akt can
directly phosphorylate mitochondrial HK II, inhibiting the release
of apoptogenic proteins [134]. We  have recently observed that the
myotonic dystrophy protein kinase (DMPK) forms a multimeric
complex with HK II and with the active form of the Tyr kinase Src
on the outer mitochondrial membrane, and that this complex pro-
tects cells from oxidative stress and from the ensuing PTP opening
[135]. In these experiments, detachment of HK II from mitochondria
ampliﬁes the oxidative stress caused by placing cells in conditions
of serum and glucose depletion. The antioxidant function of HK II
relies on its mitochondrial binding as such, and is independent of
its enzymatic activity. Indeed, it occurs in the absence of glucose
and it is enhanced by 5-thio glucose, which blocks HK II by com-
peting for glucose at the active site of the enzyme [135]. Therefore,
the antioxidant function of mitochondrial HK II, which was  also
observed by others [136], could have a key survival role by main-
taining the PTP locked. One possible mechanism to explain how HK
II takes part in ROS and PTP regulation might follow HK II interac-
tion with the fructose-2,6-bisphosphatase TIGAR, which occurs in
tumor cell mitochondria under hypoxia and limits mitochondrial
ROS levels, thus protecting from cell death [137].
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The importance of targeting mitochondrial HK II as anti-
eoplastic strategy is highlighted by the observation that HK II is
equired for tumor initiation and maintenance in mouse models
f K-Ras-driven lung cancer, as its ablation using HK II conditional
nock-out mice inhibits tumor growth without side effects [138].
K II can be dissociated from mitochondria by the enzyme inhibitor
-bromopyruvate, which causes release of apoptogenic proteins
rom mitochondria and eventually cell death [139], and by HK
I-based peptides [63,131,135], whose high degree of selectivity
oward tumor cells warrants development of clinical trials. How-
ver, further studies are needed to understand if all compounds
hat target mitochondrial HK II (e.g., metformin [140,141]) can lead
o PTP opening.
.5. Mitochondrial chaperones that inhibit PTP in tumor cells
In recent years it has been proposed that other molecular chap-
rones, in addition to CyP-D, might take part in PTP regulation of
umor cells. These and other observations raise the intriguing pos-
ibility that PTP activity is dynamically regulated by a variety of
ost-translational events, such as phosphorylations, nitrosylations,
cetylations, and by multichaperone platforms that maintain the
ppropriate folding of pore components and regulators.
TRAP1, a member of the Hsp90 protein family, is the most inten-
ively studied chaperone among those involved in pore regulation.
RAP1 expression is restricted to the mitochondrial matrix and
nner membrane, and it is increased in the majority of tumor types
xamined to date [142]. It was shown that TRAP1 protects several
ormal and transformed cell types from oxidative damage, even
f the molecular mechanism of this anti-oxidant activity was  not
lariﬁed [143–145]. Moreover, TRAP1 prevents the oxidative dam-
ge caused by cerebral ischemia in a rat model [146], and inhibits
TP opening and death of hypoxic cardiomyocytes [147]. In several
umor types, TRAP1 expression levels correlate with malignant pro-
ression [148,149], and TRAP1 protects cancer cells from toxicity
f various antineoplastic agents [144,150,151].
We have recently reported that TRAP1 interacts with succi-
ate dehydrogenase (SDH), aka respiratory complex II, inhibiting
uccinate oxidation. The consequent succinate accumulation stabi-
izes the transcription factor HIF1, triggering an oncogenic program
equired for tumor growth both in vitro and in xenograft mouse
odels [152]. As also conﬁrmed by others, down-modulation of
DH activity leads to a decrease in respiration [152,153], which
ould affect the redox equilibrium of tumor cells. Notably, SDH is
n important site of ROS generation, and blocking the catalytic site
f the SDHA subunit markedly inhibits ROS generation [154–156].
e have recently reported that inhibition of SDH by TRAP1 pro-
otes tumor growth by protecting neoplastic cells from oxidative
nsults and from the ensuing lethal opening of the PTP, and this
nti-oxidant activity of TRAP1 becomes particularly important in
onditions of nutrient paucity that mimic  those encountered in
he tumor mass during the process of unrestrained malignant
rowth [157]. Thus, TRAP1 is oncogenic not only by prompting
ccumulation of the oncometabolite succinate and the ensuing
seudohypoxic response (i.e., HIF1 activation in normoxic condi-
ions), but also by shielding tumor cells from ROS-induced PTP
pening and death.
It must be highlighted that a decrease in TRAP1 expression levels
as observed in some high grade tumors, when increasing intracel-
ular ROS could facilitate cancer cell invasion and genetic instability
reviewed in [142]). In further accord with a role in PTP regulation, it
as reported that TRAP1, and also the mitochondrial pools of Hsp90
nd Hsp60, interact with CyP-D and prevent its ability to induce the
ore in tumor cell models [50,51]. Further work is required to dis-
ect the mode of action of each of these molecular chaperones on
he PTP.ium 56 (2014) 437–445
4. Summary and conclusions
The key discovery that the PTP forms from F-ATP synthase opens
entirely new perspectives to the molecular deﬁnition of its role in
pathophysiology. The signaling pathways that affect the transition
of the F-ATP synthase from an energy-conserving to an energy-
dissipating device are of great relevance to cell death and survival,
and are exploited by cancer cells to boost their resistance to apo-
ptosis and necrosis. We  have little doubt that the rapidly increasing
understanding of pore structure and function will bring about the
design and validation of PTP-active compounds to treat cancer and
degenerative diseases.
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